---
title: "BridgeBio's acoramidis cuts risk of first heart failure event by 45% versus placebo in trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305821940.md"
description: "BridgeBio Pharma announced that acoramidis reduced the risk of first heart failure events by 45% versus placebo in the Phase 3 ATTRibute-CM trial. Real-world evidence also linked acoramidis to less worsening heart failure than tafamidis in ATTR-CM patients. Benefits emerged within the first month, and continuous treatment lowered mortality through 54 months compared to delayed initiation. Kidney function remained stable despite an early dip, with no clinically meaningful safety changes."
datetime: "2026-11-17T12:32:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305821940.md)
  - [en](https://longbridge.com/en/news/305821940.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305821940.md)
generator: "portal-rs"
---

# BridgeBio's acoramidis cuts risk of first heart failure event by 45% versus placebo in trial

-   BridgeBio Pharma announced Nov. 17, 2026, that real-world evidence linked acoramidis to less worsening heart failure than tafamidis in ATTR-CM. \* Results were presented at the 2026 American Heart Association Scientific Sessions and International Symposium on Amyloidosis. \* Phase 3 ATTRibute-CM findings showed fewer heart failure events versus placebo, with benefits emerging within the first month. \* Continuous treatment was associated with lower heart failure mortality through 54 months compared with delayed initiation. \* Kidney analyses found no clinically meaningful safety changes accompanying an early kidney-function dip; function remained stable in participants with advanced kidney disease. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170730PRIMZONEFULLFEED9879120) on November 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md)

## Related News & Research

- [Woven Health Collective Earns Two Rx Club Awards for BridgeBio Immersive Education Program](https://longbridge.com/en/news/306307213.md)
- [BridgeBio to Present New Acoramidis Data on Heart Failure Events at AHA Meeting](https://longbridge.com/en/news/304113517.md)
- [BridgeBio Reports Lower Clinical Event Risk With Acoramidis Vs Tafamidis In Heart Amyloidosis](https://longbridge.com/en/news/301541540.md)
- [BridgeBio says real-world EHR study links acoramidis to 18% lower composite risk vs tafamidis in ATTR-CM](https://longbridge.com/en/news/301513614.md)
- [BridgeBio to present new real-world study comparing acoramidis vs Pfizer’s tafamidis in ATTR-CM at HFSA 2026](https://longbridge.com/en/news/301071380.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**